EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients

Steven B Kleiboeker

Viruses · 2025

DOI: 10.3390/v17030421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Steven B Kleiboeker. Beteiligte Einrichtung: Eurofins Viracor Clinical Diagnostics, 18000 West 99th Street, Lenexa, KS 66219, USA. Hauptthemen laut MEDLINE: Cytomegalovirus, Ganciclovir, Antiviral Agents, Cytomegalovirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eurofins Viracor, Eurofins Viracor Clinical Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human cytomegalovirus (CMV) remains an important pathogen, especially for immunocompromised patients such as solid organ and hematopoietic stem cell recipients. Viral genomic mutations conferring drug resistance are an important impediment to effective CMV management and frequently lead to use of alternative antiviral drugs to treat CMV disease.

Methods

Results from 1459 de-identified patient samples with both UL54 and UL97 sequencing results were analyzed for ganciclovir (GCV) and maribavir (MBV) resistance mutations. Genomic sequencing was performed by the Sanger method and resistance mutations were identified by comparison to CMV reference strain AD169.

Results

Ganciclovir resistance was identified in 379 of 1459 (25.98%) of the samples tested, with most resistance-conferring mutations present in viral gene UL97. A total of 121 of 1459 (8.29%) samples had MBV resistance mutations, and 84 (69.42%) of the 121 samples with MBV resistance also had GCV resistance mutations. Of the 84 samples with resistance to both MBV and GCV, 35 (41.67%) had a single UL97 mutation conferring resistance to both drugs, either C480F or F342Y. The overall prevalence of C480F was increased relative to an earlier analysis of samples from this reference laboratory.

Conclusions

Although a high prevalence of CMV resistance mutations was identified, this must be taken in the context of healthcare providers submitting samples from patients with suspected CMV resistance. Most MBV-resistant samples were also resistant to GCV, suggesting that use of MBV as an alternative to GCV may benefit from genotypic resistance testing to achieve the effective control of CMV disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytomegalovirusGanciclovirAntiviral AgentsCytomegalovirus InfectionsTransplant RecipientsRibonucleosidesDrug Resistance, ViralBenzimidazolesTriazinesHumansMutationPhosphotransferases (Alcohol Group Acceptor)FemaleMaleDichlororibofuranosylbenzimidazole

Stichwörter der Autor:innen

cytomegalovirusganciclovirmaribavirresistance

Substanzen

maribavirGanciclovirAntiviral AgentsRibonucleosidesBenzimidazolesTriazinesganciclovir kinasePhosphotransferases (Alcohol Group Acceptor)Dichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • Eurofins Viracor Clinical Diagnostics, 18000 West 99th Street, Lenexa, KS 66219, USA.

Förderung

  • Eurofins Viracor
  • Eurofins Viracor Clinical Diagnostics

Zitieren

APA

Kleiboeker, S. B. (2025). Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients. Viruses. https://doi.org/10.3390/v17030421

Vancouver

Kleiboeker SB. Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients. Viruses. 2025. doi:10.3390/v17030421

BibTeX
@article{Kleiboeker2025,
  author = {Kleiboeker, Steven B},
  title = {Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17030421}
}
Kostenlos starten →